Chemclin Diagnostics Co. Ltd. A (688468) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chemclin Diagnostics Co. Ltd. A (688468) has a cash flow conversion efficiency ratio of 0.024x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥34.41 Million ≈ $5.03 Million USD) by net assets (CN¥1.41 Billion ≈ $206.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Chemclin Diagnostics Co. Ltd. A balance sheet independence to measure how much of total assets are equity-financed.
Chemclin Diagnostics Co. Ltd. A - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Chemclin Diagnostics Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 688468 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Chemclin Diagnostics Co. Ltd. A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chemclin Diagnostics Co. Ltd. A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xunlei Ltd Adr
NASDAQ:XNET
|
0.002x |
|
Beijing AriTime Intelligent Control Co Ltd
SHG:600560
|
-0.046x |
|
Clearfield Inc
NASDAQ:CLFD
|
-0.004x |
|
Ausgold Ltd
AU:AUC
|
-0.012x |
|
Thaicom Public Company Limited
BK:THCOM
|
0.017x |
|
Autolus Therapeutics plc
F:6A3A
|
-0.378x |
|
Pacific Biosciences of California
NASDAQ:PACB
|
-18.889x |
|
Hotel Majestic Cannes
PA:MLHMC
|
0.033x |
Annual Cash Flow Conversion Efficiency for Chemclin Diagnostics Co. Ltd. A (2017–2025)
The table below shows the annual cash flow conversion efficiency of Chemclin Diagnostics Co. Ltd. A from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Chemclin Diagnostics Co. Ltd. A (688468) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.41 Billion ≈ $206.46 Million |
CN¥93.90 Million ≈ $13.74 Million |
0.067x | -43.88% |
| 2024-12-31 | CN¥1.42 Billion ≈ $207.25 Million |
CN¥167.95 Million ≈ $24.58 Million |
0.119x | -4.83% |
| 2023-12-31 | CN¥1.39 Billion ≈ $203.23 Million |
CN¥173.05 Million ≈ $25.32 Million |
0.125x | -29.66% |
| 2022-12-31 | CN¥1.38 Billion ≈ $202.02 Million |
CN¥244.56 Million ≈ $35.79 Million |
0.177x | +19.94% |
| 2021-12-31 | CN¥1.28 Billion ≈ $187.11 Million |
CN¥188.86 Million ≈ $27.64 Million |
0.148x | -13.75% |
| 2020-12-31 | CN¥887.36 Million ≈ $129.85 Million |
CN¥151.95 Million ≈ $22.24 Million |
0.171x | -26.24% |
| 2019-12-31 | CN¥866.97 Million ≈ $126.87 Million |
CN¥201.27 Million ≈ $29.45 Million |
0.232x | +21.89% |
| 2018-12-31 | CN¥775.38 Million ≈ $113.46 Million |
CN¥147.68 Million ≈ $21.61 Million |
0.190x | -7.66% |
| 2017-12-31 | CN¥647.08 Million ≈ $94.69 Million |
CN¥133.46 Million ≈ $19.53 Million |
0.206x | -- |
About Chemclin Diagnostics Co. Ltd. A
Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such a… Read more